An Explorative Study of Treatment of Contact Dermatitis Due to DiabetesDevices
NCT ID: NCT04909983
Last Updated: 2022-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
17 participants
INTERVENTIONAL
2021-05-19
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Insulin Sensitivity in Patients With Atopic Dermatitis
NCT03003793
A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin
NCT02620293
Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis
NCT00643214
Skin Manifestations Associated With Adhesives in Diabetes Technology Tools
NCT04853810
Black Tea Compresses for Facial Eczema and Perioral Dermatitis
NCT02941432
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Medical Device, an occlusive patch for 3 days.
DPLX-PT1
A polymer skin patch for occlusional therapy
Control
Standard of Care
Control arm
Standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DPLX-PT1
A polymer skin patch for occlusional therapy
Control arm
Standard of care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically confirmed, active and evaluable irritant contact dermatitis (ICD)
* Age 6-20 at the time of signing the informed consent form (ICF)
* Ability to answer study questionnaires
Exclusion Criteria
* Use of occlusive therapy for the treatment of their ICD, or unwilling to refrain from this treatment for duration of study
* For any other reason considered unsuitable by the investigator
* Pregnant or of child-bearing potential unwilling to use acceptable effective contraception
6 Years
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen University Hospital at Herlev
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anna Korsgaard Berg
Principal Investigator MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Korsgaard Berg, MD
Role: PRINCIPAL_INVESTIGATOR
Pediatric Department, Herlev Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Department, Herlev Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DPLX-PT01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.